← All trials
NCT07264075
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2026
- Primary completion
- Jan 31, 2030
- Completion date
- May 31, 2030
- First posted
- Dec 4, 2025
- Last posted
- Dec 4, 2025
- Enrollment
- 780
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Groupe Oncologie Radiotherapie Tete et CouLead sponsor
- Akeso Pharmaceuticals, Inc.Collaborator
- Summit TherapeuticsCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.